Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Zealthy vs Vytora Health

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

4.8

Zealthy

Best for not currently recommended — listed for transparency and reader awareness only
★★☆☆☆2.4

Starting at $286/mo

CompoundedSemaglutideTirzepatide
Visit Zealthy →
8.7

Vytora Health

Best for Patients seeking month-to-month or 3-month-bundle compounded semaglutide or tirzepatide with the option of brand-name Mounjaro/Zepbound on a single LegitScript-approved + HIPAA-compliant platform with named pharmacy partners and transparent operating-PC disclosure. Particularly suited for patients in KS, LA, MS, NM, WV where Vytora's audio-visit option satisfies state telehealth compliance.
★★★★☆4.4

Starting at $150/mo

CompoundedBrand-Name Available (Mounjaro + Zepbound)All 50 States + DCLegitScript Approved
Visit Vytora Health →

Side-by-Side Comparison

FeatureZealthyVytora Health
Overall Score4.8/10✓8.7/10
Starting Price$286/mo✓$150/mo
Editorial Rating2.4 ★ /5✓4.4 ★ /5
Features3 features✓10 features
States Available34✓51
Compounded✓ Yes✓ Yes
Brand Name—✓ Yes
FSA/HSA Accepted——
FDA Warnings2 warnings✓None

Pros & Cons

Zealthy

Pros

  • ✓34 states served — meaningful nationwide footprint
  • ✓Asynchronous model removes friction for patients comfortable without a synchronous video visit
  • ✓Independent licensed prescribers retain full clinical authority

Cons

  • ✗TWO FDA warning letters for false/misleading marketing of compounded GLP-1s (Feb 2026 letter 717987 verified at fda.gov; September 2025 letter from secondary sources)
  • ✗Active Novo Nordisk false-advertising lawsuit: Novo Nordisk A/S et al v. Zealthy Inc., case 1:25-cv-06391 (S.D.N.Y., filed 2025-08-04), alleging trademark infringement and marketing of compounded products as 'FDA-approved alternatives'
  • ✗Active DOJ/FTC enforcement: United States v. Cerebral, Inc. et al, case 1:24-cv-21376 (S.D. Fla., amended complaint adding Zealthy Inc., Gronk Inc., founder Kyle Robertson, and others), alleging ROSCA violations (failure to disclose subscription terms, no informed consent for billing, locked cancellation), and unauthorized health-data sharing for targeted advertising
  • ✗Founder pattern of conduct: Kyle Robertson previously founded Cerebral, which settled with the FTC in June 2024 ($5M consumer redress + $10M civil penalty suspended to $2M) for similar deceptive practices. Robertson then founded Zealthy and is alleged to have continued the same conduct
  • ✗Company recently renamed FitRX/Zealthy to Gronk Inc. — rebrand pattern is itself a concerning signal in the context of active enforcement
  • ✗Continued marketing of compounded semaglutide after FDA removed it from the shortage list on 2025-02-21 (post-shortage compounding without legal authorization)
  • ✗Adds a $135/month membership fee on top of medication cost — total cash price is $286-$351/month
  • ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option

Vytora Health

Pros

  • ✓All 50 states + DC coverage with explicit per-state-modality compliance (video vs audio) disclosure
  • ✓Both compounded AND brand-name options on a single platform — uncommon (most compounded-focused providers do not offer brand)
  • ✓LegitScript Approved + HIPAA Compliant — both disclosed primary-source-verifiable
  • ✓Pharmacy partners named publicly: Vials Pharmacy (TX) + Greenwich Biosciences — uncommon transparency
  • ✓Owner / operating PC disclosed: Wasef Health, PC (Pinellas Park, FL)
  • ✓Month-to-month pricing competitive ($180 sema / $249 tirz) and 3-month bundle (17% discount) for cost-sensitive patients
  • ✓Brand-name Mounjaro and Zepbound available for patients who can self-pay $1,399/mo for FDA-approved options
  • ✓Adjunct peptide offerings (NAD+, Sermorelin) for patients pursuing broader optimization regimens

Cons

  • ✗Brand-name Mounjaro/Zepbound pricing ($1,399/mo) is near-retail; insured patients should pursue PA through traditional pharmacy + LillyDirect Self Pay Journey Program ($449-$699/mo) for better economics
  • ✗Compounded tirzepatide tier ($249/mo) is above the lowest market floor ($149-199/mo) — Vytora pricing is mid-market for compounded
  • ✗Specific dose-tier pricing not publicly broken out — pricing shown as 'all doses included' which is favorable but means high-dose patients pay the same as low-dose patients
  • ✗Initial consultation cost not disclosed on public-facing pricing page (some providers free, some $99)
  • ✗Limited primary-source-verifiable state licensure detail per individual prescriber (most multi-state telehealth platforms have this gap)

Our Verdict

Winner: Vytora HealthScore: 8.7/10

Vytora Health edges out Zealthy with a higher overall score of 8.7/10 and is particularly strong for Patients seeking month-to-month or 3-month-bundle compounded semaglutide or tirzepatide with the option of brand-name Mounjaro/Zepbound on a single LegitScript-approved + HIPAA-compliant platform with named pharmacy partners and transparent operating-PC disclosure. Particularly suited for patients in KS, LA, MS, NM, WV where Vytora's audio-visit option satisfies state telehealth compliance.. Zealthy remains a solid alternative, especially if you're looking for not currently recommended — listed for transparency and reader awareness only.

Get Started with Zealthy →Get Started with Vytora Health →

Glossary references

Key terms in this article, linked to their canonical definitions.

Related comparisons

Continue exploring Zealthy and Vytora Health head-to-heads in the same category.

Or see the full category ranking.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.